ACORN CAPITAL ADVISORS, LLC — 13F Holdings & Portfolio
CIK 2054410 · latest 13F-HR filed 2026-08-14
ACORN CAPITAL ADVISORS, LLC manages $366.5M in 13F-reported U.S. long-equity assets across 20 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are CGON (21.94%), URGN (16.80%), TRVI (10.92%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 3, added to 13, and trimmed 5.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 2626
NEW YORK, NY 10170
$366.5M
Long-equity book
20
Distinct positions
2026-06-30
Filed 2026-08-14
+1 / −3 / ↑13 / ↓5
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- UROGEN PHARMA LTD$31.5M +104.7%
- CANDEL THERAPEUTICS INC$18.8M +109.3%
- TREVI THERAPEUTICS INC$14.4M +56.3%
- KARYOPHARM THERAPEUTICS INC$13.2M +825.2%
- JADE BIOSCEINCES INC$10.9M +98.4%
Top Trims
- PROTARA THERAPEUTICS INC-$2.4M -26.7%
- VERASTEM INC-$2.2M -27.9%
- LEONABIO, INC.-$691.6K -10.6%
- JASPER THERAPEUTICS-$638.1K -51.4%
- BIOATLA INC-$417.4K -48.3%
Exited Positions
- TERNS PHARMACEUTICALS INC$92.1M
- CARDIF ONCOLOGY INC$2.9M
- X4 PHARMACEUTICALS INC$966.6K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CG ONCOLOGY INC | CGON | 156944100 | $80.4M | 21.94% | 1,131,500 | SH |
| 2 | UROGEN PHARMA LTD | URGN | M96088105 | $61.6M | 16.80% | 1,673,420 | SH |
| 3 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $40.0M | 10.92% | 2,144,844 | SH |
| 4 | CANDEL THERAPEUTICS INC | CADL | 137404109 | $36.0M | 9.83% | 3,497,948 | SH |
| 5 | PUMA BIOTECHNOLOGY INC | PBYI | 74587V107 | $33.5M | 9.14% | 4,131,299 | SH |
| 6 | JADE BIOSCEINCES INC | JBIO | 008064206 | $21.9M | 5.98% | 986,760 | SH |
| 7 | BICARA THERAPEUTICS | BCAX | 055477103 | $19.1M | 5.21% | 643,381 | SH |
| 8 | KARYOPHARM THERAPEUTICS INC | KPTI | 48576U205 | $14.8M | 4.05% | 1,518,113 | SH |
| 9 | ONKURE THERAPEUTICS INC | OKUR | 68277Q105 | $12.9M | 3.53% | 2,839,674 | SH |
| 10 | HELUS PHARMA INC. | HELP | 23256X407 | $10.2M | 2.78% | 1,540,266 | SH |
| 11 | PROTARA THERAPEUTICS INC | TARA | 74365U107 | $6.7M | 1.83% | 1,752,115 | SH |
| 12 | AURA BIOSCIENCES INC | AURA | 05153U107 | $6.6M | 1.80% | 929,077 | SH |
| 13 | LEONABIO, INC. | LONA | 04746L203 | $5.8M | 1.59% | 634,539 | SH |
| 14 | VERASTEM INC | VSTM | 92337C203 | $5.6M | 1.53% | 1,469,153 | SH |
| 15 | WHITEHAWK THERAPEUTICS INC | WHWK | 00032Q104 | $5.2M | 1.42% | 1,139,363 | SH |
| 16 | Q32 BIO INC. | QTTB | 746964105 | $2.8M | 0.75% | 216,171 | SH |
| 17 | EUGENE THERAPEUTICS | ENGN | 29286X101 | $2.2M | 0.60% | 1,271,257 | SH |
| 18 | JASPER THERAPEUTICS | JSPR | 471871202 | $604.0K | 0.16% | 1,438,159 | SH |
| 19 | BIOATLA INC | BCAB | 09077B104 | $447.6K | 0.12% | 108,126 | SH |
| 20 | VYNE THERAPEUTICS INC | VYNE | 92941V308 | $926 | 0.00% | 1,425 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $366.5M | 20 | 0001636587-26-000067 |
| 2026-03-31 | 2026-05-15 | $351.8M | 22 | 0001636587-26-000029 |
| 2025-12-31 | 2026-02-17 | $295.1M | 21 | 0001636587-26-000005 |
| 2025-09-30 | 2025-11-17 | $197.0M | 20 | 0001636587-25-000060 |